Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process
- PMID: 23211844
- DOI: 10.1038/ajg.2012.117
Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process
Abstract
We report the findings and outputs of an international expert opinion process to develop a definition of early Crohn's disease (CD) that could be used in future disease-modification trials. Nineteen experts on inflammatory bowel diseases held an international expert opinion meeting to discuss and agree on a definition for early CD to be used in disease-modification trials. The process included literature searches for the relevant basic-science and clinical evidence. A published preliminary definition of early CD was used as the basis for development of a proposed definition that was discussed at the expert opinion meeting. The participants then derived a final definition, based on best current knowledge, that it is hoped will be of practical use in disease-modification trials in CD.
Similar articles
-
Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD.Gastroenterology. 2021 Apr;160(5):1452-1460.e21. doi: 10.1053/j.gastro.2020.10.065. Epub 2021 Jan 6. Gastroenterology. 2021. PMID: 33421515
-
Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus.Endoscopy. 2009 Jul;41(7):618-37. doi: 10.1055/s-0029-1214790. Epub 2009 Jul 8. Endoscopy. 2009. PMID: 19588292 Review.
-
Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America.J Pediatr Gastroenterol Nutr. 2007 May;44(5):653-74. doi: 10.1097/MPG.0b013e31805563f3. J Pediatr Gastroenterol Nutr. 2007. PMID: 17460505
-
Management of Crohn's disease in adults.Am J Gastroenterol. 2009 Feb;104(2):465-83; quiz 464, 484. doi: 10.1038/ajg.2008.168. Epub 2009 Jan 6. Am J Gastroenterol. 2009. PMID: 19174807
-
The Manitoba IBD Index: evidence for a new and simple indicator of IBD activity.Am J Gastroenterol. 2009 Jul;104(7):1754-63. doi: 10.1038/ajg.2009.197. Epub 2009 May 19. Am J Gastroenterol. 2009. PMID: 19455122
Cited by
-
Diagnosis and natural history of preclinical and early inflammatory bowel disease.Ann Gastroenterol. 2020 Sep-Oct;33(5):443-452. doi: 10.20524/aog.2020.0508. Epub 2020 Jun 22. Ann Gastroenterol. 2020. PMID: 32879589 Free PMC article. Review.
-
Impact of inflammatory bowel disease on daily life: an online survey by the Korean Association for the Study of Intestinal Diseases.Intest Res. 2017 Jul;15(3):338-344. doi: 10.5217/ir.2017.15.3.338. Epub 2017 Jun 12. Intest Res. 2017. PMID: 28670230 Free PMC article.
-
Efficacy of early intervention on the bowel damage and intestinal surgery of Crohn's disease, based on the Lémann index.BMC Gastroenterol. 2020 Dec 11;20(1):421. doi: 10.1186/s12876-020-01575-7. BMC Gastroenterol. 2020. PMID: 33308166 Free PMC article.
-
Shorter Crohn's Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies.Gastro Hep Adv. 2024 Mar 7;3(4):539-550. doi: 10.1016/j.gastha.2024.02.008. eCollection 2024. Gastro Hep Adv. 2024. PMID: 39131711 Free PMC article.
-
First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?Nat Rev Gastroenterol Hepatol. 2013 Jun;10(6):345-51. doi: 10.1038/nrgastro.2013.31. Epub 2013 Mar 5. Nat Rev Gastroenterol Hepatol. 2013. PMID: 23458890 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
